Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

BSH 2019 | Real world data for CLL management

Anthony Mato • 1 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the current focus of real world data for chronic lymphocytic leukemia (CLL) management. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Anthony Mato

The importance of genomic testing in CLL prognosis 1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
Time-limited vs continuous therapy in CLL treatment 1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
Updates on non-covalent BTK inhibitors and their place in CLL treatment 2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
Pirtobrutinib resistance in CLL: early findings 1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101 1:45
MRD-guided treatment with sonrotoclax plus obinutuzumab in treatment-naive CLL: BGB-11417-101
Marc Hoffman • 7 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib 3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL 1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals